Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers#651242
• Cytokines and immunologic checkpoint molecules in predicting success of allergen immunotherapy.#209408
• Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma#1103715
• Characterizing Postoperative T and B Cell Dysfunction in Cancer Surgery Patients, Using COVID-19 as a Model Antigen#869646
• Invalidation des immune checkpoints PD-1 et TIGIT dans des lymphocytes T CD8+ spécifiques de tumeur : conséquences fonctionnelles et utilisation en immunothérapie#268566